|Bid||168.95 x 800|
|Ask||178.38 x 800|
|Day's range||173.32 - 174.76|
|52-week range||108.89 - 184.97|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||67.28|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Nov 2012|
|1y target est||N/A|
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.